G蛋白偶联受体C类第5组成员D导向免疫治疗在多发性骨髓瘤中的新兴作用:进展、耐药与联合策略
本文综述GPRC5D的结构特征与表达谱及其与疾病生物学和预后的关系,汇总靶向GPRC5D的抗体偶联药物、双特异与三特异抗体及CAR T/NK细胞疗法在复发/难治多发性骨髓瘤中的研究进展,并讨论抗原逃逸与联合策略优化等挑战。
要点
- GPRC5D在骨髓瘤细胞高表达且正常组织表达少,是具前景的免疫治疗靶点
- 靶向GPRC5D的ADC、双/三特异抗体及CAR T/NK疗法在复发/难治骨髓瘤中显示令人鼓舞的疗效
- 抗原逃逸与联合策略优化是主要挑战,需大规模前瞻性试验确定治疗定位
核心结论
- GPRC5D有望成为继B细胞成熟抗原之后多发性骨髓瘤免疫治疗的领先下一代靶点
- 随着靶向GPRC5D药物在临床开发中推进,大规模前瞻性试验对确定其治疗定位和改善患者结局至关重要
研究设计与样本
- 综述,梳理GPRC5D的结构特征与表达谱,并汇总靶向GPRC5D的抗体偶联药物、双特异与三特异抗体及CAR T/NK细胞疗法在复发/难治多发性骨髓瘤中的进展
主要发现
- GPRC5D在骨髓瘤细胞中高表达且具选择性,在正常组织中表达极少
- 靶向GPRC5D的抗体偶联药物、双特异与三特异抗体及CAR T/NK细胞疗法在复发/难治多发性骨髓瘤中均显示令人鼓舞的疗效
- 抗原逃逸与联合策略优化是靶向GPRC5D治疗面临的关键挑战
临床怎么用
- 作者指出,随着靶向GPRC5D药物推进临床开发,需大规模前瞻性试验界定其治疗定位并改善患者结局
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a clonal malignancy of plasma cells characterized by frequent relapse and therapeutic resistance. G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a promising immunotherapeutic target due to its high and selective expression in MM cells and minimal presence in normal tissues. This review outlines the structural features and expression profile of GPRC5D, emphasizing its relevance to disease biology and prognosis. We highlight recent advances in GPRC5D-targeted therapies, including antibody-drug conjugates (ADCs), bispecific and trispecific antibodies and chimeric antigen receptor T (CAR T)/natural killer (NK)-cell therapies, all demonstrating encouraging efficacy in relapsed/refractory MM. Key challenges, such as antigen escape and the need for optimized combination strategies, are also discussed. As GPRC5D-targeted agents advance through clinical development, large-scale prospective trials will be essential to define their therapeutic positioning and improve patient outcomes. GPRC5D is poised to become a leading next-generation target in MM immunotherapy following B-cell maturation antigen.
引用
- Wang X, Cui Y, Wang Y, et al. Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies. Br J Haematol. 2025. PMID: 40879107. doi:10.1111/bjh.70116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。